Nuclear Medicine Radioisotopes Market to Land US$ 19.04 billion by the end of 2033, Opines Fact.MR

The nuclear medicine radioisotopes market is anticipated to grow at a high-value CAGR of 8%. As a result, it is anticipated that by the end of 2033, the global market will have grown from a valuation of US$ 8.82 billion to US$ 19.04 billion.

In order to diagnose and treat a wide range of ailments, such as cancer, cardiac disease, and neurological disorders, nuclear medicine uses radioactive chemicals or radiopharmaceutical synthesizers. High-tech cameras allow medical personnel to monitor the movement of the radioactive tracers. Additionally, positron emission tomography (PET) and single-photon emission computed tomography (SPECT) tests are two crucial imaging modalities in the field of nuclear medicine.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8311?AS

Key Pioneers

• Bayer AG
• Bracco Imaging SpA
• Cardinal Health, Inc.
• GE Healthcare
• Hologic, Inc.
• Lantheus Medical Imaging, Inc.
• Medtronic PLC
• NTP Radioisotopes SOC Ltd.
• Positron Corporation
• Siemens Healthineers

Key Statistics Supporting the Surge

• The global nuclear medicine radioisotopes market is expected to increase at a CAGR of 8% from 2023 to 2033.
• Germany's market for nuclear medicine radioisotopes is predicted to expand at a CAGR of 6.5% during the projected period.
• Global sales of technetium-99m (Tc-99m) radioisotopes are expected to rise at a CAGR of 9% during the forecast period.
• Demand for thallium-201 (Tl-201) radioisotopes is predicted to expand at a CAGR of 6.5% during the next 10 years.

"North America & Europe are leading regional markets for nuclear medicine radioisotopes due to the presence of key market players," says a Fact.MR analyst.

Recent Market Developments

• Technetium-99m (Tc-99m), the most popular medical radioisotope, will be more readily available worldwide starting in March 2021 due to a collaboration between IBA (Ion Beam Applications SA) and NorthStar Medical Radioisotopes LLC.
• To commercialize and develop advanced alpha-emitting radiopharmaceutical and combination therapies for cancer therapy, Fusion Pharmaceuticals, a leading Canadian radiopharmaceutical company, announced collaboration with Anglo-Swedish pharmaceutical behemoth AstraZeneca in November 2020.
• Curium announced in June 2021 that it had acquired Austrian pharmaceutical company IASON to expand its presence in the region.
• The first-of-its-kind therapeutic radioisotope production plant was officially opened as part of the NorthStar Medical Radioisotopes expansion event in October 2021.

Industry Research

• By Radioisotope Type :

o Technetium-99m (Tc-99m)
o Thallium-201 (Tl-201)
o Gallium-67 (Ga-67)
o Iodine (I-123)

• By Application :

o Cardiology
o Oncology
o Neurology
o Lymphoma
o Thyroid

• By End User :

o Hospitals
o Diagnostic Centers
o Specialty Clinics
o Education & Research Institutes

• By Region :

o North America
o Latin America
o Europe
o East Asia
o South Asia & Oceania
o MEA

Predominant Questions Answered in This Report Are:

1. Which segments will perform well in the products and services market over the forecasted years?
2. In which markets companies should authorize their presence.
3. What are the forecasted growth rates for the products and services market?
4. What are the long-lasting defects of the industry?
5. How share market changes their values by different manufacturing brands?
6. What are the qualities and shortcomings of the key players?
7. What are the major end results and effects of the five strengths study of industry?

What makes Fact.MR report stand out from others?

Fact.MR follows a six-point mechanism known as E.V.O.L.V.E. (Evaluate. Visualize. Overcome. Leverage. Verify. Eradicate.). This mechanism focuses on almost all the factors in a definite manner to provide the best research report for the market stakeholders.

• Evaluate: A Fact.MR report evaluates every small aspect that can prove to be a growth generator for the market, thus, making it different and special from other reports.

• Visualize: The authors involved in the research activities visualized the post-COVID-19 era so that the key stakeholders of market get an overview and helps them take certain steps to ensure continuous growth during the forecast period.

• Overcome: The report scrutinizes on points that can prove to be an achilles heel to the market and assists to create strategies to overcome the obstacles that may hinder the growth of the market.

• Leverage: The market can leverage certain aspects that can prove beneficial for the increase in growth rate. Fact.MR covers all the points on which the key stakeholders can leverage upon.

• Verify: Research is done systematically to assure validation of all the aspects covered in the report. All the points are rechecked and verified thoroughly to avoid flaws and fake information.

• Eradicate: Last but not the least, this aspect helps the key stakeholder eradicate all the obstacles that come between the growth rate and the market.

Get Customization on this Report for Specific Research Solutions -
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8311?AS

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Email : sales@factmr.com

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That's why focus on offering insights that can actually make a difference to bottom-lines.

This release was published on openPR.